Work

Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-ct179

Authors: Anthony W. Tolcher, Michael L. Meyers, Dmitry Gabrilovich, Fang Wang, Jane Trepel, Min-Jung Lee, Emmett Schmitt, Christine Quaranto, Serap Sankoh, David Tamang, Peter Ordentlich

Institutions: South Texas Accelerated Research Therapeutics, Syndax Pharmaceuticals (United States), The Wistar Institute, National Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2886811182

Cites:

Cited by: 1

Related to: 10